Matt Blosl joined DexCare as CEO at a critical inflection point, bringing expertise from six previous venture-backed companies. Rather than driving initial growth, his role centered on taking a well-established business to its next maturation level. He focuses on creating a culture of controlled failure and innovation, telling his team “I want us to fail more” because not failing means not pushing boundaries. He’s also strategically filled experience gaps by hiring people who have successfully navigated similar growth stages.
The company’s “co-innovation at scale” philosophy challenges traditional SaaS thinking that customization is negative. DexCare treats every client implementation as its own innovation opportunity, made scalable through AI. This addresses the healthcare “trilemma”: increasing patient volume, decreasing physician availability, and shrinking margins. DexCare’s platform helps health systems match patients with appropriate providers while identifying unused capacity in existing networks.
AI has fundamentally transformed DexCare’s operations at three levels: internal operations, existing products, and new innovation. Teams now build alpha versions over weekends that previously took six months. However, Matt stresses focus, warning that AI can make companies “massively unfocused very quickly.” He sees the current moment as unique because every healthcare player is simultaneously rethinking their business model, creating unprecedented opportunities for collaboration and advancement.
